PRFX Overview

PRF Technologies Ltd is an Israel-based company engaged primarily in pharmaceutical sector. The Company is a producer of speciality pharmaceuticals as well as energy analytics powered by artificial intelligence (AI). The Firm develops reformulated and sustained‑release drug‑delivery platforms that combine proven generic medicines with proprietary extended‑release systems to improve patient outcomes. One of the Company's products is PRF‑110 - a ropivacaine‑based formulation designed to deliver localised, extended postoperative analgesia. The Company also advances OcuRingTD, a bio‑erodible drug‑release ring integrated with intraocular lenses for continuous delivery of medications in cataract surgery.In the energy analytics sector the Company operates DeepSolar platform that provides AI‑powered monitoring, forecasting, and optimisation tools for solar asset performance.

Wall Street analysts forecast PRFX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRFX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

PRF Technologies Ltd revenue for the last quarter amounts to -7.34M USD, increased 226.15

PRF Technologies Ltd. EPS for the last quarter amounts to -4954000.00 USD, increased 147.33

PRF Technologies Ltd (PRFX) has 2 emplpoyees as of March 11 2026.

Today PRFX has the market capitalization of 2.09M USD.